Pulmonary HTN Drugs

Question 1

Pulmonary HTN Risk Factors (2)

Answer 1

Bone Morphogenic Protein II gene (BMPR2)

Fenfluramine/Phentermine diet pills

Question 2

Vasoreactivity Testing

Responder (2) vs Non-Responder

Answer 2

Responder if Pulmonary P decreases by 10+mmHg
Responders treated with CCB’s

Non-Repsonders contraindicated to CCB’s

Question 3

Prostanoids

Effects (3) and General Adverse Effects (4)

Answer 3

Mimic endogenous prostacyclins to:
Vasodilate
Decrease smooth muscle proliferation
Decrease platelet aggregation

Headache
N/V/D
Flushing
Jaw Pain

Question 4

Epoprostenol

Class, Delivery and Adverse Effects (2)

Answer 4

Prostanoid

Continuous IV

Sepsis
Clogged catheter

Question 5

Treprostinil

Class, Delivery (2) and Unique Characteristics (2)

Answer 5

Prostanoid

Continuous IV or Subcutaneous

Has longer half-life than Epoprostenol
Doesn’t require refrigeration like Epoprostenol

Question 6

Iloprost

Class, Delivery and Adverse

Answer 6

Prostanoid

Inhaled

Fainting from hypotension

Question 7

Selexipeg

Drug Class and Delivery

Answer 7

Prostanoid

Oral

Question 8

Endothelin Antagonists

Examples (2) MOA and Effects (2)

Answer 8

Bosentan
Ambrisentan

Inhibits endothelin receptors to:
Decrease vasoconstriction
Decrease smooth muscle proliferation

Question 9

Bosentan

MOA and Complications (4)

Answer 9

Non-selectively blocks ETa and ETb receptors

Hepatotoxic
Teratogenic
Interacts with warfarin
Interacts with contraceptives

Question 10

Ambrisentan

MOA and Complication

Answer 10

Selectively blocks ETa receptors

Teratogenic

Question 11

PDE5 Inhibitors

Examples (2), MOA and Effects (2)

Answer 11

Sildenafil
Vardenafil

Inhibits PDE5 to increase cGMP

Smooth muscle relaxation
Vasodilation

Question 12

Riociugat

MOA and Effect (2)

Answer 12

Increases soluble guanalate cyclase to increase cGMP

Smooth muscle relaxation and vasodilation